Home/admin

About admin

This author has not yet filled in any details.
So far admin has created 21 blog entries.

BUFFALO BIOLABS, LLC TO PARTICIPATE AT BIO INTERNATIONAL 2014 CONVENTION IN SAN DIEGO.

Buffalo BioLabs, LLC (BBL) is pleased to announce its participation in BIO International 2014, the largest and most influential biotech convention in the world, to take place in San Diego June 23-26, 2014.  The BBL booth can be found at New York State Pavilion # 1559.

Buffalo Biolabs, LLC (BBL), founded in 2009 by Dr. Andrei V. Gudkov, PhD, DSci, is a Contract Research Organization (CRO) focused on preclinical services and drug discovery, primarily in the fields of oncology, immunology and wound care. BBL operates from its headquarters on the Buffalo Niagara Medical Campus.

BUFFALO BIOLABS, LLC CONTRACTED BY INCURON LLC AS PREFERRED PRECLINICAL PARTNER.

Buffalo Biolabs, LLC (BBL) and Incuron LLC announced today that Incuron has retained the services of Buffalo Biolabs for preclinical murine studies. The studies, to be conducted in 2014, will advance and enhance the understanding of the efficacy and mechanism of work of Incuron’s flagship compound CBLO137. According to Vladimir Tezov, CEO of Bioprocess Capital, one of Incuron’s investors, Incuron previously “outsourced to BBL several research tasks involving new assay and model development and the outcome exceeds our most optimistic expectations. I expect us broadening our relationships with this company.”

Buffalo Biolabs, LLC (BBL), founded in 2009 by Dr. Andrei V. Gudkov, PhD, DSci, is a Contract Research Organization (CRO) focused on preclinical services and drug discovery, primarily in the fields of oncology, immunology and wound care. BBL operates from its headquarters in Buffalo Niagara Medical Campus.

BUFFALO BIOLABS, LLC STRENGTHENS ITS WORKFORCE WITH NEW LABORATORY AND PRECLINICAL SERVICES PERSONNEL.

Buffalo Biolabs, LLC (BBL) and Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that because of maturation of CBLI’ development pipeline and a reduced need for certain services, it has transferred laboratory and preclinical services personnel to BBL, an entity affiliated with one of the CBLI’s co-founders, Dr. Andrei Gudkov, PhD, DSci. CBLI has executed a service agreement providing for continued access to BBL team on an as-needed basis. As part of the transfer, Dmitry Tyomkin, MBA has agreed to join BBL as President and CEO. Previously, Dmitry served as President and CEO of Panacela Labs, a majority-owned subsidiary of Cleveland Biolabs. 

Buffalo Biolabs, LLC (BBL), founded in 2009 by Dr. Andrei V. Gudkov, PhD, DSci, is a Buffalo, NY based Contract Research Organization (CRO) focused on preclinical services and drug discovery, primarily in the fields of oncology, immunology and wound care. BBL operates from its headquarters in Buffalo Niagara Medical Campus.

Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist.

Read publication

Burdelya LG, Brackett CM, Kojouharov B, Gitlin II, Leonova KI, Gleiberman AS, Aygun-Sunar S, Veith J, Johnson C, Haderski GJ, Stanhope-Baker P, Allamaneni S, Skitzki J, Zeng M, Martsen E, Medvedev A, Scheblyakov D, Artemicheva NM, Logunov DY, Gintsburg AL, Naroditsky BS, Makarov SS, Gudkov AV.

Proc Natl Acad Sci U S A. 2013 May 14;110(20):E1857-66. doi: 10.1073/pnas.1222805110. Epub 2013 Apr 29.

BUFFALO BIOLABS, LLC AWARDED A $300,000 FEDERAL GRANT TOWARDS PANCREATIC CANCER RESEARCH.

Buffalo Biolabs, LLC (BBL) announced today that it has been awarded a phase I Small Business Technology Transfer (STTR) grant. This is a second STTR grant won by BBL. The new grant supports the work conducted by the company and its collaborators in the field of preclinical oncology. Dr. Katerina Gurova, a researcher at Roswell Park Cancer Insitute and a co-Investigator for the grant commented: “We are pleased to have received the support from Small Business Administration. The funds will be instrumental to advance our research of pathways affecting pancreatic cancer”.

The federal STTR program expands funding opportunities in federal innovation research and development by supporting public/private sector partnerships to include joint venture opportunities for small businesses and nonprofit research institutions.

Buffalo Biolabs, LLC (BBL), founded in 2009 by Dr. Andrei V. Gudkov, PhD, DSci, is a Buffalo, NY based Contract Research Organization (CRO) focused on preclinical services and drug discovery, primarily in the fields of oncology, immunology and wound care. BBL operates from its headquarters in Buffalo Niagara Medical Campus.